TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 19041063

Group type: EXPERIMENTAL
Intervention: ATO 0.15 mg/kg i.v. x 7 days + melphalan 200 mg/m2 i.v. over 2 days + AA 1000 mg i.v. over 7 days
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: ATO 0.25 mg/kg i.v. x 7 days + melphalan 200 mg/m2 i.v. over 2 days + AA 1000 mg i.v. over 7 days
Number of subjects: 48

Group type: COMPARATOR
Intervention: No ATO + melphalan 200 mg/m2 i.v. over 2 days + AA 1000 mg i.v. over 7 days
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: All treatment arms (ATO + AA + melphalan)
Number of subjects: 48
Study: 17081400

Group type: EXPERIMENTAL
Intervention: Soy protein isolate (40 g soy protein, 118 mg isoflavones)
Number of subjects: 213

Group type: COMPARATOR
Intervention: Cassin placebo
Number of subjects: 213
Study: 14608283

Group type: EXPERIMENTAL
Intervention: E/A ratio at tips of mitral valve leaflets
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Atrial filling fraction
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Isovolumic relaxation time
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: E-wave deceleration time
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: E-wave propagation rate
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: E'/A' ratio of diastolic excursion of lateral mitral annulus
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Doppler parameters of LV diastolic function
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: E/A at tips of mitral valve
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Doppler tissue-derived E'/A'
Number of subjects: 40
Study: 10644315

Group type: EXPERIMENTAL
Intervention: Ipratropium 40 microg
Number of subjects: 72

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Not applicable
Number of subjects: 72
Study: 8824689

Group type: EXPERIMENTAL
Intervention: 400 mg nefazodone once daily in the morning (treatment 1)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 400 mg nefazodone once daily in the evening (treatment 2)
Number of subjects: 24

Group type: COMPARATOR
Intervention: 200 mg nefazodone twice daily (treatment 3)
Number of subjects: 24
Study: 1454350

Group type: EXPERIMENTAL
Intervention: Augmentation laser panretinal photocoagulation (MORE)
Number of subjects: 35

Group type: COMPARATOR
Intervention: No additional treatment (NOMORE)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: All study patients
Number of subjects: 35
Study: 3966664

Group type: EXPERIMENTAL
Intervention: Spinal anesthesia with bupivacaine 0.25 mg X kg‐1
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Halothane/oxygen anesthesia
Number of subjects: 32

Group type: COMPARATOR
Intervention: Bupivacaine 0.25 mg X kg‐1 im without surgery (volunteers)
Number of subjects: 32
Study: 31679187

Group type: EXPERIMENTAL
Intervention: Lumbar anatomy parameters measured via CT scanning
Number of subjects: 476
Study: 29679660

Group type: EXPERIMENTAL
Intervention: Aerobic training (N=75)
Number of subjects: 304

Group type: EXPERIMENTAL
Intervention: Resistance training (N=78)
Number of subjects: 304

Group type: EXPERIMENTAL
Intervention: Combined aerobic and resistance training (N=75)
Number of subjects: 304

Group type: COMPARATOR
Intervention: Non-exercising control (N=76)
Number of subjects: 304
Study: 26785715

Group type: EXPERIMENTAL
Intervention: Decision aid alone (n=168)
Number of subjects: 341

Group type: EXPERIMENTAL
Intervention: Decision aid plus risk assessment (n=173)
Number of subjects: 341
Study: 24662322

Group type: EXPERIMENTAL
Intervention: Anti-CGRP monoclonal antibody (up to 2000 mg)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study: 22168128

Group type: EXPERIMENTAL
Intervention: Cold blood cardioplegia
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Crystalloid cardioplegia
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 30
Study: 20712261

Group type: EXPERIMENTAL
Intervention: levobupivacaine 0.50%
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: racemic bupivacaine 0.50%
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: levobupivacaine-hyaluronidase 10 IU x ml(‐1)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: racemic bupivacaine-hyaluronidase 10 IU x ml(‐1)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control group (hyaluronidase)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Comparison of groups
Number of subjects: 120
Study: 17510208

Group type: EXPERIMENTAL
Intervention: LV5FU2 + CPT‐11
Number of subjects: 400
Study: 16637748

Group type: EXPERIMENTAL
Intervention: Positive face flanked by negative faces
Number of subjects: 0

Group type: COMPARATOR
Intervention: Negative face flanked by positive faces
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nonemotional stimuli
Number of subjects: 0
Study: 14582817

Group type: EXPERIMENTAL
Intervention: Desloratadine, 5 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Diphenhydramine, 50 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 10975012

Group type: EXPERIMENTAL
Intervention: Ofloxacin (total 15 mg/kg, 2 doses)
Number of subjects: 135

Group type: COMPARATOR
Intervention: Nalidixic acid (NA: 55 mg/kg daily for 5 days)
Number of subjects: 135

Group type: COMPARATOR
Intervention: Nalidixic acid (NA)
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Ofloxacin
Number of subjects: 135
Study: 8630595

Group type: EXPERIMENTAL
Intervention: Oxygen
Number of subjects: 38

Group type: COMPARATOR
Intervention: Air
Number of subjects: 38
Study: 1574933

Group type: EXPERIMENTAL
Intervention: Whole-body cold therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Hot mud-pack therapy
Number of subjects: 0
Study: 3882071

Group type: EXPERIMENTAL
Intervention: Infusion of contrast material (60 to 350 mL)
Number of subjects: 193

Group type: COMPARATOR
Intervention: No infusion of contrast material
Number of subjects: 193

Group type: EXPERIMENTAL
Intervention: Infusion of contrast material in high-risk group
Number of subjects: 193

Group type: COMPARATOR
Intervention: No infusion of contrast material in high-risk group
Number of subjects: 193
Study: 30353444

Group type: EXPERIMENTAL
Intervention: Ticagrelor 180 mg + Morphine
Number of subjects: 1862

Group type: COMPARATOR
Intervention: Ticagrelor 180 mg
Number of subjects: 1862
Study: 28183002

Group type: EXPERIMENTAL
Intervention: UCBfree
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: UCBfree/TSB ratio
Number of subjects: 72

Group type: COMPARATOR
Intervention: TSB-based phototherapy treatment
Number of subjects: 72
Study: 25500982

Group type: EXPERIMENTAL
Intervention: Interventional arm of the EAGLE study
Number of subjects: 34
Study: 23320487

Group type: EXPERIMENTAL
Intervention: risperidone LAI
Number of subjects: 50

Group type: COMPARATOR
Intervention: oral atypical antipsychotic medication
Number of subjects: 50
Study: 21574750

Group type: EXPERIMENTAL
Intervention: Value and relatedness cues in predicting likelihood of remembering items (JOLs)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Control of study time for each item based on value and relatedness
Number of subjects: 0
Study: 18293602

Group type: EXPERIMENTAL
Intervention: Ceramic ball attachments (ruby)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Titanium ball attachments
Number of subjects: 40
Study: 16531596

Group type: EXPERIMENTAL
Intervention: Five-minute booster seat training
Number of subjects: 225

Group type: EXPERIMENTAL
Intervention: Five-minute booster seat training and free booster seat with installation
Number of subjects: 225

Group type: COMPARATOR
Intervention: Standard discharge instructions
Number of subjects: 225
Study: 15545855

Group type: EXPERIMENTAL
Intervention: 4 doses of Pn‐PD at 2, 4, 6 and 12‐15 months
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: 3 doses of Pn‐PD at 2, 4 and 6 months and 1 dose of 23‐valent polysaccharide vaccine (PncPS) at 12‐15 months
Number of subjects: 154

Group type: COMPARATOR
Intervention: 3 doses of hepatitis B vaccine at 2, 4 and 6 months and Pn‐PD at 12‐15 months
Number of subjects: 154
Study: 10770194

Group type: EXPERIMENTAL
Intervention: Metyrapone administration in normal men; n = 8
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo in normal men; n = 8
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Replacement therapy in patients with chronic hypocortisolism; n = 8
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: After withdrawal of prednisone in patients with chronic hypocortisolism; n = 8
Number of subjects: 24
Study: 9327779

Group type: EXPERIMENTAL
Intervention: Atorvastatin 10 mg QD for 12 weeks increasing to 20 mg QD for 12 weeks
Number of subjects: 84

Group type: COMPARATOR
Intervention: Fenofibrate 100 mg TID for 24 weeks
Number of subjects: 84
Study: 1588979

Group type: EXPERIMENTAL
Intervention: Inhaled methoxamine (10 mg)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 3904456

Group type: EXPERIMENTAL
Intervention: Prophylactic amnioinfusion
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (no amnioinfusion)
Number of subjects: 0
Study: 31904715

Group type: EXPERIMENTAL
Intervention: VL5 (5% velocity loss)
Number of subjects: 28

Group type: COMPARATOR
Intervention: VL20 (20% velocity loss)
Number of subjects: 28
Study: 29341843

Group type: EXPERIMENTAL
Intervention: Telemonitoring
Number of subjects: 338

Group type: EXPERIMENTAL
Intervention: Telemedicine
Number of subjects: 338

Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 338
Study: 26888908

Group type: EXPERIMENTAL
Intervention: Ertapenem (1.0 g once daily)
Number of subjects: 565

Group type: COMPARATOR
Intervention: Piperacillin/tazobactam (4.5 g every 8 h)
Number of subjects: 565
Study: 23846567

Group type: EXPERIMENTAL
Intervention: Community health worker tool
Number of subjects: 198

Group type: COMPARATOR
Intervention: WHO clinical staging
Number of subjects: 198
Study: 22770792

Group type: EXPERIMENTAL
Intervention: 10‐mL 1% lidocaine paracervical block
Number of subjects: 50

Group type: COMPARATOR
Intervention: No local anesthetic
Number of subjects: 50
Study: 20031291

Group type: EXPERIMENTAL
Intervention: Ultrasonography-guided measurement of tumor thickness
Number of subjects: 13

Group type: COMPARATOR
Intervention: Conventional resection method
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: New technique using elastic needles with a metal core
Number of subjects: 13
Study: 17110397

Group type: EXPERIMENTAL
Intervention: HP-hMG (MENOPUR)
Number of subjects: 731

Group type: COMPARATOR
Intervention: rFSH (GONAL-F)
Number of subjects: 731
Study: 16219143

Group type: EXPERIMENTAL
Intervention: Traditional Chinese Medicine (TCM)
Number of subjects: 294

Group type: EXPERIMENTAL
Intervention: Combination (TCM plus NP regimen)
Number of subjects: 294

Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 294
Study: 12168125

Group type: EXPERIMENTAL
Intervention: Paratrend 7 system (continuous blood gas monitoring)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Standard system of blood gas analysis (intermittent sampling)
Number of subjects: 10
Study: 10640121

Group type: EXPERIMENTAL
Intervention: Training in patient-centred consulting (GPs 0.5 days; nurses 1.5 days; two optional follow-up half-days)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Training in patient-centred consulting
Number of subjects: 49
Study: 7832387

Group type: EXPERIMENTAL
Intervention: Recombinant human erythropoietin (RHE) at a loading dose of 300 U/kg iv 3 times/week for 1 week followed by 150 U/kg 3 times/week (N = 13) or 100 U/kg 3 times/week (N = 7)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (no RHE)
Number of subjects: 40
Study: 1977080

Group type: EXPERIMENTAL
Intervention: Low-dose zidovudine (300 mg daily)
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Medium-dose zidovudine (600 mg daily)
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: High-dose zidovudine (1500 mg daily)
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Acyclovir (4.8 g) with zidovudine
Number of subjects: 67

Group type: COMPARATOR
Intervention: All doses of zidovudine (300 mg, 600 mg, 1500 mg)
Number of subjects: 67
Study: 344850

Group type: EXPERIMENTAL
Intervention: Theophylline 125 mg
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Ephedrine SO4 30 mg
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 30870235

Group type: EXPERIMENTAL
Intervention: Tetrabenazine (TBZ)
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Deutetrabenazine (DTBZ)
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Valbenazine (VBZ)
Number of subjects: 135
Study: 28872918

Group type: EXPERIMENTAL
Intervention: Edaravone (E-E)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Edaravone (P-E)
Number of subjects: 0
Study: 26686385

Group type: EXPERIMENTAL
Intervention: hIL1bQb vaccine (900 µg, six injections)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: hIL1bQb vaccine
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study: 24971700

Group type: EXPERIMENTAL
Intervention: Exercise (n=12)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Passive sitting (Control)
Number of subjects: 25
Study: 23039299

Group type: EXPERIMENTAL
Intervention: Magnesium (10 mmol bolus, 5 mmol/h infusion for 6 hours)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 39
Study: 19240614

Group type: EXPERIMENTAL
Intervention: Sural nerve harvesting (Group 1: n = 10, Group 2: n = 6, Group 3: n = 8)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Sural nerve harvesting (Group 1: n = 10)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Sural nerve harvesting (Group 3: n = 8)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group (Group 4: n = 24)
Number of subjects: 24
Study: 17325559

Group type: EXPERIMENTAL
Intervention: Alanyl-glutamine (AG) 24 g/d for 10 days
Number of subjects: 107

Group type: COMPARATOR
Intervention: Glycine (G) 25 g/d for 10 days (control)
Number of subjects: 107
Study: 16562417

Group type: EXPERIMENTAL
Intervention: Individual TLFB administration
Number of subjects: 104

Group type: COMPARATOR
Intervention: Group TLFB administration
Number of subjects: 104
Study: 12196420

Group type: EXPERIMENTAL
Intervention: Purified t10c12 CLA (3.4 g/day)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: CLA mixture (3.4 g/day)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 9459332

Group type: EXPERIMENTAL
Intervention: Free T4 (fT4) levels
Number of subjects: 472
Study: 7572573

Group type: EXPERIMENTAL
Intervention: Various predictors including QRS duration, coronary artery bypass grafting, basal heart rate, diastolic blood pressure, diabetes mellitus, ejection fraction, ease of suppression
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Various predictors including thrombolysis, coronary artery bypass grafting, diuretic use, heart rate, calcium channel blocker use, QRS duration
Number of subjects: 0
Study: 2692821

Group type: EXPERIMENTAL
Intervention: Betamethasone dipropionate 0.05% cream, augmented formulation (AF), once-daily application
Number of subjects: 244

Group type: COMPARATOR
Intervention: Fluocinonide 0.05% cream, twice-daily application
Number of subjects: 244
Study: 57451

Group type: EXPERIMENTAL
Intervention: 1 alpha‐hydroxycholecalciferol (1alpha‐H.C.C.) 1 mug daily for eleven weeks
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 31859682

Group type: EXPERIMENTAL
Intervention: Self-tracking
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Learning and goal setting (moderate level)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Clinically meaningful use (combination of learning, goal setting, and self-tracking)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Generic app use (intensity and duration)
Number of subjects: 0
Study: 27974302

Group type: EXPERIMENTAL
Intervention: MRI erosion scores at Weeks 12 and 24
Number of subjects: 1022

Group type: EXPERIMENTAL
Intervention: MRI osteitis scores at Weeks 12 and 24
Number of subjects: 1022

Group type: EXPERIMENTAL
Intervention: MRI changes in synovitis at Weeks 12 and 24
Number of subjects: 1022
Study: 25375780

Group type: EXPERIMENTAL
Intervention: EX/RP
Number of subjects: 100

Group type: COMPARATOR
Intervention: risperidone
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Both EX/RP and risperidone
Number of subjects: 100
Study: 23874586

Group type: EXPERIMENTAL
Intervention: External beam radiation in 10 fractions of 3 Gy, 5 fractions a week for 2 consecutive weeks with oral capecitabine 700 mg/m² twice daily throughout radiation therapy
Number of subjects: 29
Study: 21772125

Group type: EXPERIMENTAL
Intervention: High circulating syndecan‐1
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Syndecan‐1
Number of subjects: 75
Study: 18931896

Group type: EXPERIMENTAL
Intervention: Perindopril 8 mg once daily
Number of subjects: 12218

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12218
Study: 16689402

Group type: EXPERIMENTAL
Intervention: Family management styles (FMSs)
Number of subjects: 0
Study: 15558087

Group type: EXPERIMENTAL
Intervention: Manual toothbrush (Group M)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Electrically powered toothbrush (Group E)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Manual toothbrush and chlorhexidine gluconate (CHX) spray (Group MC)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Electrically powered toothbrush and CHX spray (Group EC)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Chlorhexidine gluconate (CHX) spray (Group C)
Number of subjects: 59
Study: 15568420

Group type: EXPERIMENTAL
Intervention: Continuous running non-absorbable or slowly absorbed suture (polydioxanone)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lateral paramedian incision
Number of subjects: 0

Group type: COMPARATOR
Intervention: Transverse abdominal incisions
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Greater number of stitches with a suture length to wound ratio of at least 4:1
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Minimal tension on closure
Number of subjects: 0
Study: 10529323

Group type: EXPERIMENTAL
Intervention: Nadroparin 6 group (86 anti-Xa IU/kg for 6 days)
Number of subjects: 3468

Group type: EXPERIMENTAL
Intervention: Nadroparin 14 group (86 anti-Xa IU/kg for 14 days)
Number of subjects: 3468

Group type: EXPERIMENTAL
Intervention: Nadroparin 14 group
Number of subjects: 3468

Group type: COMPARATOR
Intervention: Unfractionated heparin group
Number of subjects: 3468
Study: 7768249

Group type: EXPERIMENTAL
Intervention: Somatostatin (IV loading dose 125 micrograms, followed by IV infusion of 125 micrograms.h‐1)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Loxiglumide (10 mg.kg‐1.h‐1)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Control saline
Number of subjects: 9
Study: 2180577

Group type: EXPERIMENTAL
Intervention: Urografin
Number of subjects: 287

Group type: EXPERIMENTAL
Intervention: iopamidol
Number of subjects: 287

Group type: EXPERIMENTAL
Intervention: iohexol
Number of subjects: 287
Study: 7419830

Group type: EXPERIMENTAL
Intervention: Lodoxamide tromethamine (0.01 mg)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Lodoxamide tromethamine (0.1 mg)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Lodoxamide tromethamine (1.0 mg)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 29252140

Group type: EXPERIMENTAL
Intervention: MOBIDERM Autofit night arm sleeve (night-user group)
Number of subjects: 40

Group type: COMPARATOR
Intervention: No night compression (no night-user group)
Number of subjects: 40
Study: 25763776

Group type: COMPARATOR
Intervention: Inferior vena cava clamping
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Reverse Trendelenburg position
Number of subjects: 50

Group type: COMPARATOR
Intervention: Trendelenburg position
Number of subjects: 50

Group type: COMPARATOR
Intervention: Hypoventilation anesthesia
Number of subjects: 50
Study: 23276415

Group type: EXPERIMENTAL
Intervention: Calaxo screw
Number of subjects: 60

Group type: COMPARATOR
Intervention: Milagro screw
Number of subjects: 60
Study: 20630631

Group type: EXPERIMENTAL
Intervention: Mandibular condylar movement exercises
Number of subjects: 148

Group type: COMPARATOR
Intervention: No exercise (control)
Number of subjects: 148
Study: 18806833

Group type: EXPERIMENTAL
Intervention: G‐CSF+EPO
Number of subjects: 28

Group type: COMPARATOR
Intervention: G‐CSF
Number of subjects: 28
Study: 17141945

Group type: EXPERIMENTAL
Intervention: Intermittent androgen suppression (IAS)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Subsequent cycles of androgen withdrawal
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Androgen withdrawal
Number of subjects: 29
Study: 15090958

Group type: EXPERIMENTAL
Intervention: Albumin (25 g of a 25% solution every 8 hrs for a total of nine doses)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo (normal saline administered in identical fashion and volume)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Albumin treatment group
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 20
Study: 11231447

Group type: EXPERIMENTAL
Intervention: Accelerated alteplase
Number of subjects: 1784

Group type: COMPARATOR
Intervention: Streptokinase monotherapies
Number of subjects: 1784

Group type: COMPARATOR
Intervention: No prior CABG
Number of subjects: 1784

Group type: EXPERIMENTAL
Intervention: Patients with prior CABG
Number of subjects: 1784
Study: 9473973

Group type: EXPERIMENTAL
Intervention: Keeping-track of the same changing attribute
Number of subjects: 0

Group type: COMPARATOR
Intervention: Keeping-track of different changing attributes
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Increasing number of information events intervening between presentation and recall
Number of subjects: 0
Study: 7531868

Group type: EXPERIMENTAL
Intervention: Therevac SB
Number of subjects: 10

Group type: COMPARATOR
Intervention: Bisacodyl suppositories
Number of subjects: 10
Study: 29373170

Group type: EXPERIMENTAL
Intervention: Part video clips
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: 30-second video clips
Number of subjects: 7

Group type: COMPARATOR
Intervention: Full video clips
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Shorter video clips (part and 30-second)
Number of subjects: 7
Study: 27490086

Group type: EXPERIMENTAL
Intervention: Diabetes-specific preparation protocol (DSP)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Conventional bowel preparation protocol (CBP)
Number of subjects: 150
Study: 24796059

Group type: EXPERIMENTAL
Intervention: Combined therapy (sword-like needle + chiropractic spinal manipulation)
Number of subjects: 138

Group type: COMPARATOR
Intervention: Chiropractic spinal manipulation
Number of subjects: 138